tiprankstipranks
Trending News
More News >

4DMedical Secures $13.9 Million to Boost Lung Diagnostics Commercialization

Story Highlights
  • 4DMedical Limited raised $13.9 million through an oversubscribed SPP and Placement.
  • Funds will accelerate commercialization of lung diagnostics and support FDA submission of CT:VQ™.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
4DMedical Secures $13.9 Million to Boost Lung Diagnostics Commercialization

4DMedical Ltd ( (AU:4DX) ) has shared an update.

4DMedical Limited has successfully completed an oversubscribed Securities Purchase Plan (SPP), raising $8.4 million, which, combined with a previous $5.5 million Placement, totals $13.9 million. These funds will support the company’s efforts to commercialize its lung diagnostics portfolio and advance the FDA submission of its CT:VQ™ technology. The capital raised positions 4DMedical to enhance its market presence and continue developing innovative respiratory diagnostic tools, benefiting shareholders and the broader healthcare industry.

More about 4DMedical Ltd

4DMedical Limited (ASX:4DX) is a global medical technology company specializing in advanced respiratory imaging solutions. The company leverages cutting-edge imaging and AI-powered technologies to provide detailed insights into lung function, facilitating earlier and more accurate diagnoses of respiratory diseases.

YTD Price Performance: -25.00%

Average Trading Volume: 927,646

Technical Sentiment Signal: Buy

Current Market Cap: A$153.7M

For detailed information about 4DX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App